These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A diterpenoid compound, excisanin A, inhibits the invasive behavior of breast cancer cells by modulating the integrin β1/FAK/PI3K/AKT/β-catenin signaling.
    Author: Qin J, Tang J, Jiao L, Ji J, Chen WD, Feng GK, Gao YH, Zhu XF, Deng R.
    Journal: Life Sci; 2013 Nov 04; 93(18-19):655-63. PubMed ID: 24044886.
    Abstract:
    AIM: Excisanin A, a diterpenoid compound purified from Isodon macrocalyxin D, has anti-cancer properties with little toxicity. In this study, the anti-invasive effects of excisanin A on breast cancer cells and its molecular mechanism of action were investigated. MAIN METHODS: MTT, wound healing, transwell chamber and cell adhesion assays were utilized to investigate the effects of excisanin A on MDA-MB-231 and SKBR3 cells. Western blotting, real-time PCR, RNA interference and luciferase reporter assays were employed to determine the molecular mechanism of action of excisanin A. KEY FINDINGS: Treating MDA-MB-231 and SKBR3 cells with 10-40μM excisanin A significantly inhibited cell migration and invasion and suppressed the mRNA and protein levels of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in a dose-dependent manner. Excisanin A efficiently abolished integrin β1 expression and reduced the phosphorylation of the downstream kinases focal adhesion kinase (FAK) and Src. Excisanin A inhibited the phosphorylation of phosphoinositide 3-kinase (PI3K), AKT and glycogen synthase kinase 3 beta (GSK3β) and down-regulated β-catenin expression and the luciferase activity of the transcription factor LEF-1. Moreover, treating breast cancer cells with siRNA targeting integrin β1 inhibited cell invasion and migration. SIGNIFICANCE: These results demonstrated that excisanin A inhibited invasion by suppressing MMP-2 and MMP-9 expression; the integrin β1/FAK/PI3K/AKT/β-catenin signaling pathway was involved in this process. Therefore, excisanin A might be a potential anti-metastatic chemotherapeutic agent for the treatment of breast cancer.
    [Abstract] [Full Text] [Related] [New Search]